GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Botanix Pharmaceuticals Ltd (OTCPK:BXPHF) » Definitions » Debt-to-Asset

BXPHF (Botanix Pharmaceuticals) Debt-to-Asset : 0.01 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Botanix Pharmaceuticals Debt-to-Asset?

Botanix Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.18 Mil. Botanix Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.37 Mil. Botanix Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $62.98 Mil. Botanix Pharmaceuticals's debt to asset for the quarter that ended in Dec. 2024 was 0.01.


Botanix Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Botanix Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Botanix Pharmaceuticals Debt-to-Asset Chart

Botanix Pharmaceuticals Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.01 0.01 - -

Botanix Pharmaceuticals Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.01

Competitive Comparison of Botanix Pharmaceuticals's Debt-to-Asset

For the Biotechnology subindustry, Botanix Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Botanix Pharmaceuticals's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Botanix Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Botanix Pharmaceuticals's Debt-to-Asset falls into.


;
;

Botanix Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Botanix Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Jun. 2024 is calculated as

Botanix Pharmaceuticals's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Botanix Pharmaceuticals  (OTCPK:BXPHF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Botanix Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Botanix Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Botanix Pharmaceuticals Business Description

Traded in Other Exchanges
Address
41 - 47 Colin Street, Suite 3, West Perth, WA, AUS, 6005
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1204 - Atopic Dermatitis, and BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is Derived from Australia.

Botanix Pharmaceuticals Headlines